Trial Profile
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (Asymptomatic and Gout)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Ruzinurad (Primary) ; Benzbromarone
- Indications Hyperuricaemia
- Focus Therapeutic Use
- Acronyms FOCUS
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Mar 2021 Results published in the Rheumatology
- 05 Aug 2019 Status changed from recruiting to completed.
- 19 Jun 2017 New trial record